Business Context and Reporting Period
This Form 8-K is a current report filed by Social Capital Suvretta Holdings Corp. III (SCS) on April 28, 2022. The filing relates to a previously announced business combination with ProKidney LP. The primary purpose of this report is to disclose the scheduling of a joint analyst day between SCS and ProKidney.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This document serves as a notification of an upcoming event rather than a financial results report.
Material Changes
No material changes to financial performance or operational status are reported in this filing. The document solely announces the logistics for the joint analyst day scheduled for April 28, 2022, at 8:00 a.m. Eastern Time.
Guidance, Outlook, and Management Commentary
- Analyst Day: ProKidney and SCS will host a joint analyst day on April 28, 2022.
- Materials: Presentation materials are attached as Exhibit 99.1 and incorporated by reference.
- Access: A live webcast is available on the ProKidney and SCS websites.
- Legal Disclaimer: The information in Item 7.01 and Exhibit 99.1 is furnished, not "filed" under Section 18 of the Exchange Act, and is not subject to the liability of that section. It shall not be incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the content of the Analyst Day presentation (Exhibit 99.1) for specific business outlook and financial projections.
- Confirm the status of the business combination agreement between ProKidney LP and Social Capital Suvretta Holdings Corp. III.
- Review the live webcast or recording for management commentary on the combined entity's strategy.
- Note that this 8-K does not contain audited financial statements or updated financial metrics.